Ginkgo plans to strategically partner with leading companies in mature markets to create synthetic biology-based spinouts, something it has already done in ag-bio.
Spurred to develop new microfluidic chip technology, 10x told customers not to worry about the transition but told a court there would be "guaranteed hitches."
The firm's technology uses DNA sequencing, artificial intelligence, and a microbial database to interpret soil health and identify potential disease risk.
